254 related articles for article (PubMed ID: 27720202)
21. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract][Full Text] [Related]
22. LDR brachytherapy offers superior tumor control to single-fraction HDR prostate brachytherapy: A prospective study.
Jimenez-Garcia IE; Sabater S; Martinez-Gutierrez R; Sanchez-Galiano P; Berenguer-Serrano R; Castro-Larefors S; Rey-Lopez I; Ruiz-Herrero B; Sánchez-Prieto R; Rovirosa A; Arenas M; Gonzalez-Suarez HA
Prostate; 2023 Aug; 83(11):1068-1075. PubMed ID: 37150842
[TBL] [Abstract][Full Text] [Related]
23. From low-dose-rate to high-dose-rate brachytherapy in lip carcinoma: Equivalent results but fewer complications.
Guinot JL; Arribas L; Tortajada MI; Crispín V; Carrascosa M; Santos M; Mut A; Vendrell JB; Pesudo C; Chust ML
Brachytherapy; 2013; 12(6):528-34. PubMed ID: 23850275
[TBL] [Abstract][Full Text] [Related]
24. Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity.
Romano KD; Pugh KJ; Trifiletti DM; Libby B; Showalter TN
Brachytherapy; 2017; 16(2):378-386. PubMed ID: 28139420
[TBL] [Abstract][Full Text] [Related]
25. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
26. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
Lertsanguansinchai P; Lertbutsayanukul C; Shotelersuk K; Khorprasert C; Rojpornpradit P; Chottetanaprasith T; Srisuthep A; Suriyapee S; Jumpangern C; Tresukosol D; Charoonsantikul C
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1424-31. PubMed ID: 15275728
[TBL] [Abstract][Full Text] [Related]
27. Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy.
Tward JD; Jarosek S; Chu H; Thorpe C; Shrieve DC; Elliott S
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1443-1453. PubMed ID: 27325475
[TBL] [Abstract][Full Text] [Related]
28. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
[TBL] [Abstract][Full Text] [Related]
29. [Clinical evaluation based on cost-effectiveness].
Inoue T; Inoue T
Gan To Kagaku Ryoho; 1998 Jan; 25(1):13-9. PubMed ID: 9464324
[TBL] [Abstract][Full Text] [Related]
30. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
Morton GC; Hoskin PJ
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
[TBL] [Abstract][Full Text] [Related]
31. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers.
Varela Cagetti L; Zemmour C; Salem N; Minsat M; Ferrè M; Mailleux H; Giovaninni M; Lelong B; De Chaisemartin C; Ries P; Poizat F; Tallet A; Moureau-Zabotto L
Brachytherapy; 2019; 18(6):814-822. PubMed ID: 31515067
[TBL] [Abstract][Full Text] [Related]
32. Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer.
Ong WL; Evans M; Papa N; Williams S; Millar J
J Med Imaging Radiat Oncol; 2023 Oct; 67(7):789-795. PubMed ID: 37828817
[TBL] [Abstract][Full Text] [Related]
33. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments.
Visser AG; van den Aardweg GJ; Levendag PC
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):497-505. PubMed ID: 8567354
[TBL] [Abstract][Full Text] [Related]
34. HDR versus LDR gynecological brachytherapy revisited.
Scalliet P; Gerbaulet A; Dubray B
Radiother Oncol; 1993 Aug; 28(2):118-26. PubMed ID: 8248552
[TBL] [Abstract][Full Text] [Related]
35. Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.
Thaker NG; Pugh TJ; Mahmood U; Choi S; Spinks TE; Martin NE; Sio TT; Kudchadker RJ; Kaplan RS; Kuban DA; Swanson DA; Orio PF; Zelefsky MJ; Cox BW; Potters L; Buchholz TA; Feeley TW; Frank SJ
Brachytherapy; 2016; 15(3):274-282. PubMed ID: 26916105
[TBL] [Abstract][Full Text] [Related]
36. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
[TBL] [Abstract][Full Text] [Related]
37. [Present and future in brachytherapy--from the discovery of radium to the 21st century].
Inoue T; Inoue T
Gan To Kagaku Ryoho; 1999 Aug; 26(9):1254-60. PubMed ID: 10478177
[TBL] [Abstract][Full Text] [Related]
38. A precise and simple isodose-volume-based verification method for HDR and LDR brachytherapy plans.
Schiefer H; Heinze S; Glatzer M
Brachytherapy; 2023; 22(3):400-406. PubMed ID: 36635203
[TBL] [Abstract][Full Text] [Related]
39. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
40. Determination of the appropriate fraction number and size of the HDR brachytherapy for cervical cancer.
Liu WS; Yen SH; Chang CH; Yang KM; Wu YP; Chen KY
Gynecol Oncol; 1996 Feb; 60(2):295-300. PubMed ID: 8631555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
